ZNF365抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human liver cancer tissue, Primary antibody: P12443(ZNF365 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12443(ZNF365 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The ZNF365 antibody is designed to target the zinc finger protein 365 (ZNF365), a member of the zinc finger protein family involved in transcriptional regulation and DNA repair. ZNF365 exists in multiple isoforms generated by alternative splicing, with the long isoform (ZNF365L) implicated in maintaining genomic stability by interacting with DNA repair proteins like BRCA1. and the short isoform (ZNF365S) associated with telomere length regulation. Research suggests ZNF365 plays a role in cell cycle control, apoptosis, and tumor suppression.

Antibodies against ZNF365 are widely used to study its expression patterns, subcellular localization, and interactions in various biological contexts. Immunoblotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) are common applications. Studies using these antibodies have linked ZNF365 dysregulation to diseases such as cancer (e.g., breast cancer, melanoma), age-related macular degeneration (AMD), and inflammatory conditions. For example, reduced ZNF365 expression correlates with poor prognosis in certain cancers, while genetic variants near the ZNF365 locus are associated with AMD susceptibility.

These antibodies also help dissect ZNF365's dual roles in DNA damage response and telomere maintenance, providing insights into its tissue-specific functions. Validation of ZNF365 antibodies often includes knockout cell lines or siRNA-mediated silencing to confirm specificity. Overall, ZNF365 antibodies serve as critical tools for exploring its molecular mechanisms and therapeutic potential in human diseases.